LOGIN
Golimumab treatment provides superior treatment of rheumatoid arthritis
May 2013
Golimumab treatment provides superior treatment of rheumatoid arthritis
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial
Lancet. 2009 Jul 18;374(9685):210-21. Epub 2009 Jun 26Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
461 patients with rheumatoid arthritis who have undergone treatment with a TNF-alpha inhibitor previously were randomized to three groups. 2 groups were treated with either a 50 mg or 100 mg dosage of Golimumab and the third group received a placebo injection. The results indicated that treatment with Golimumab at either dose provided significant improvements in rheumatoid arthritis measures (ARC2...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.